(NASDAQ: NWBO)

Bullish Northwest Biotherapeutics

OverviewRecent Price52 Week Range1 Month Range

$6.00$3.79 - $10.64$5.25 - $6.83

Avg Daily Volume 459,382PE Ratio 0.0

Earnings Per ShareYear EPS2015(E) -$1.60

CapitalizationShares Outstanding 62MMMarket Capitalization $374MM

Predictive RangeExpected Movement $6.53 - $7.44

Investment Highlights

•

•

•

PATTERN SCAN predicts the price of NWBO expected to move up in the coming weeks based on the appearance of a 'Piercing Lines' pattern. Specifically, a SS Heikin Ashi 2 variant of Piercing Lines has been detected. The target is $7.87. GATS predicts NWBO will move up in the coming weeks. Target is $7.01. SQUEEZETRIGGER predicts that when NWBO closes above $5.86, we expect a short squeeze to begin that could quickly drive the price of NWBO considerably higher.

• VALUATION NWBO has a current squeeze value of $10.76 which means the stock is undervalued compared to its Price of $6.00.

Northwest Biotherapeutics, Inc., a development stage biotechnology company, discovers and develops immunotherapy products to treat cancers in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient s own immune system to attack cancer. The companys products include DCVax-L, which is under Phase III brain cancer trial for treating brain and ovarian cancer; DCVax-Direct that is under Phase I/II clinical for various types of inoperable solid tumor cancers; and DCVax-Prostate for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

How WealthMakers Market Reads Work:

WealthMakers Market Reads™ provide you with market performance predictions based on proprietarytechnologies, trading algorithms and data to help you make better, more informed investment decisions.Here's a quick review of our predictive technologies:

EARNINGS Most stock price histories show random or unpredictable movements aroundearnings reports. But some repeat the same pattern quarter after quarter, year after year.Earnings predicts probability, price move and length of move before and after all US stockearnings reports.

•

FRICTION FACTOR Friction Factor is based on the relationship between the price of a stockand the volume at which it's bought and sold. Normal and abnormal Friction factor patterns canhelp you time your buying and selling decisions for maximum earnings potential.

•

GATS The Global Automated Trading System (GATS) combines neural networks and geneticalgorithms to reduce investment risks. GATS selects the highest probability trades in stocks,bonds, options, commodities, currencies and private equities, delivering precise, predictive andprofitable data.

•

GROUP SECTOR Certain institutions can exert buying or selling pressure over an entireindustry group, pushing prices higher. Group Sector identifies stocks that most closely matchtheir group's movement and generate powerful group consensus trading signals to help youprofit from the herd mentality.

•

PATTERN SCAN This technology automatically tracks "Trigger Events" that positively ornegatively affect the value of a stock — or its perceived value among analysts — ranging fromprice fluctuations to natural disasters and political shifts. The results reveal patterns that canpredict market movements.

•

EVENTS Events describe the current technical situation in your stock. It displays the technicals,trend conditions and seasonal factors and automatically discovers how that stock has performedin the trading days following the occurrences of the event or combination of events. Thistechnology automatically scans using complex historical queries based on what event is takingplace right now in the stock. It then displays the probability, expected return and number oftrading days for the expected move.

•

RegSHO NAKED SHORTS Tracks EVERY failure to deliver in all US stocks and allThreshold Security Lists daily for which stocks have naked short positions

•

SEASONALITY Seasonality analyzes more than 20 years of data to determine if stocks have along or short seasonal bias, how many trading days the move is expected to last, the probabilityof that move and the percentage move the stock is expected to make based on the seasonal bias.

•

SQUEEZE TRIGGER Our proprietary database of more than 3,500,000,000 short saletransactions allows us to calculate the exact price at which the total short interest is short in eachstock. Squeeze Trigger Alerts let you know exactly when a short squeeze will start and how totrade profitably.

•

VALUATION A stock's value is a function of its forecasted earnings per share and forecastedearnings growth, as well as profitability, interest and inflation rates. Valuation use these metricsto determine at what price a stock is undervalued or overvalued, so that you can makeinvestment decisions accordingly.

•

INSIDER Significant stock sales or purchases by company "insiders" (officers or directors) canbe a predictor of future price movements — up or down. The Insider strategy tracks theseactions and correlates them with historical data to give you an investment edge.

•

Pattern Scan

Tracks "Trigger Events" that positively or negatively affect the value of a stock.

Northwest Biotherapeutics (NASDAQ: NWBO) is predicted to go up in coming weeks based on bullish technical trends that have appeared in the recent performance of the stock. NWBO has demonstrated Piercing Lines strategy SS Heikin Ashi 2 with a strength of 1.0/5. The higher the strength, the higher the probability of an accurate prediction.

The price of NWBO expected to move up in the coming weeks.•PatternScan has detected that a 'SS Heikin Ashi 2' pattern has appeared.•Specifically, a SS Heikin Ashi 2 variant of Piercing Lines has been detected.•This indicates a high probablity that NWBO will move up in the coming weeks.•

GATS

Reduces risk by selecting the highest probability trades across market indices.

Northwest Biotherapeutics (NASDAQ: NWBO) is expected to go up as bullish signals have been generated by top equity trading strategies. This trading system is designed to identify high probability reversion to mean trading candidates. It looks to go long immediately following strong sell-offs, and goes short after sharp run ups. Its trades are short term and hone in on the irrational decisions of emotional traders around these extreme moves.

The price of NWBO expected to move up in the coming weeks.•Suggested stop level of $5.55 to limit potential trading losses.•

Squeeze Trigger

We have a proprietary database of all trading in US stocks and maintain massive databases of short saleand naked short sale time and sales data, along with short squeeze SqueezeTrigger prices. We are theonly firm that knows the exact price that a short squeeze will start in every US stock.

The Cumulative Squeeze Trigger price for NWBO is $5.86.

This means that when NWBO closes above $5.86, we expect a short squeeze to begin that could quickly drive the price of NWBO considerably higher.

Friction Factor

Friction Factor determines if there is normal or abnormal behavior in the price action of the stock when compared to the buying vs. selling trading statistics. It shows us how many more shares of buying than selling it takes to move a stock higher by 1 cent, or how many more shares of selling than buying it takes to drop a stock by 1 cent. Here is how to understand Friction Factor:

If Friction Factor is positive, more buying than selling caused NWBO's price to rise•If Friction Factor is negative, more selling than buying caused NWBO's price to fall•If Friction Factor is 0, there was no discernable activity either way•If Friction Factor is abnormal, it means that more buying than selling caused the price to dropwhich is evidence of manipulative activity. In some cases more selling than buying can causethe price to increase. While this is rare, it must be noted as well. Friction Factor raw data.

•

ValuationShort Squeeze Value is a measure of a stock's current worth if a short squeeze occurs. NWBO has acurrent squeeze value of $10.76 per share. Squeeze Value is computed from the average positiveFriction Factor of 4,041 shares. When dividing 1,979,137 shares shorted (2015 shorts) by average Friction Factor we get a projected price move of $4.90. The target price is $5.86 + $4.90 = $10.76.

General Results

Past success in predictions regarding all predictions on the WealthMakers platform.

Our prediction engine has a track record that is second to none. See for our results.

Read Type Avg Return Avg Maturity Days Hits Misses % AccurateInsider 16.124 78.25 10961 526 95.42%SqueezeTrigger 12.519 21.98 8823 589 93.74%Valuation 14.484 26.96 4201 302 93.29%Group Correlation 6.701 14.44 2880 238 92.37%Seasonality 7.338 15.15 47921 4644 91.17%PatternScan 8.559 11.49 171257 25135 87.20%Events 6.907 11.24 3900 604 86.59%GATS 5.4 7.89 57105 11439 83.31%Earnings 8.566 10.27 22948 4660 83.12%Naked Shorts 14.067 10.91 2592 670 79.46%Friction Factor 7.215 3.63 6463 1854 77.71%

Recent Headlines

NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum PR Newswire(Fri, Jan 23)

How this CEO keeps her 40-year-old luxury clothing company fresh and growing at American City Business Journals(Fri, Jan 9)

NW Bio To Present At Biotech Showcase Conference PR Newswire(Thu, Jan 8)

NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online(Tue, Dec 30)

NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to EDGAR Online(Mon, Dec 29)

NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure EDGAR Online(Mon, Dec 22)

NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets EDGAR Online(Mon, Dec 15)

NW BIO RECAPS 2014 PROGRESS, PROVIDES DCVAX-DIRECT TRIAL UPDATE AT OPPENHEIMER'S 25TH ANNUAL HEALTHCARE CONFERENCE PR Newswire(Thu, Dec 11)

NORTHWEST BIOTHERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online(Tue, Dec 2)

NORTHWEST BIOTHERAPEUTICS INC Financials EDGAR Online Financials(Thu, Nov 27)

10-Q for Northwest Biotherapeutics, Inc. Company Spotlight(Fri, Nov 21)

Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind at TheStreet(Fri, Nov 21)

NORTHWEST BIOTHERAPEUTICS INC Files SEC form 10-Q, Quarterly Report EDGAR Online(Wed, Nov 19)

NW BIO ANNOUNCES FINANCINGS TOTALING $35 MILLION TO EXPAND AND ACCELERATE DCVAX®-L AND DCVAX®-DIRECT PROGRAMS PR Newswire(Wed, Nov 19)

NW BIO MAKING A JOINT POSTER PRESENTATION ON ITS DCVAX-DIRECT TRIAL AT THE 29TH ANNUAL SITC MEETING PR Newswire(Fri, Nov 7)

QUESTIONS?

ACCOUNT SUPPORT 949-230-7680 EMAIL - tom@wealthmakers.com

About WealthMakers

WealthMakers gives institutional and individual investors an exclusive advantage in making precise,predictive and profitable trading decisions. Our proprietary technologies — Earnings, Seasonality,Squeeze Trigger, Group Sector and GATS — apply artificial intelligence, proprietary algorithms, marketdata and research to help our clients realize exponential returns. Find out more at WealthMakers.com.

All material herein was prepared by WealthMakers, based upon information believed to be reliable. Theinformation contained herein is not guaranteed by WealthMakers to be accurate, and should not beconsidered to be all-inclusive. The companies that are discussed in this opinion have not approved thestatements made in this opinion. This opinion contains forward-looking statements that involve risks anduncertainties. This material is for informational purposes only and should not be construed as an offer orsolicitation of an offer to buy or sell securities. WealthMakers is not a registered investment advisor inthe State of California. Please consult a broker before purchasing or selling any securities viewed on ormentioned herein. WealthMakers has received $1,116 per month for data provided twelve monthlyreports. WealthMakers affiliates, officers, directors and employees do not own shares of the companymentioned in this report, but may from time to time buy/sell the shares discussed in this opinion and mayprofit from those trades. Market commentary provided by Thomas Ronk, a registered investment advisorand commodities trading advisor in California. WealthMakers will not advise as to when it decides tosell and does not and will not offer any opinion as to when others should sell; each investor must makethat decision based on his or her judgment.

All Rights Reserved. Copyright 2015 WealthMakers